Compare TG Therapeutics Inc (TGTX) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Victoria's Secret & Co — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Victoria's Secret & Co trades at $76 (market cap $6.26B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Victoria's Secret & Co nearer its low. Which is the better fit depends on your goals.
| TGTX | VSXY | |
|---|---|---|
Market Cap | $8.53B | $6.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $99.97 |
52-Week Low | $26.94 | $25.56 |
Enterprise Value | $8.74B | $8.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Victoria's Secret (VSXY) trades at $78.47, up 3.85% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains solid fundamentals with a 45.27% ROE and improving cash flow projections. Recent news highlights PINK brand growth and beauty segment acceleration, though the stock faces near-term pressure from sales concerns despite earnings outperformance.
The outlook remains cautiously optimistic with a $97.33 consensus price target representing 24% upside potential. Key opportunities include sustained PINK growth and margin expansion, while risks involve competitive pressures and execution challenges. Analyst consensus leans bullish with 60% buy ratings, but investors should monitor Q3 2026 results for confirmation of the turnaround trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
